-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

Benzinga·09/16/2026 12:10:46
Listen to the news
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.